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Association of Methylenetetrahydrofolate Reductase (MTHFR-677 and 
MTHFR-1298) Genetic Polymorphisms with Occlusive Artery Disease and 
Deep Venous Thrombosis in Macedonians
Aim To analyze the association of methylenetetrahydrofolate reduc-
tase polymorphisms (MTHFR-677 and MTHFR-1298) with occlusive 
artery disease and deep venous thrombosis in Macedonians.
Methods We examined 83 healthy respondents, 76 patients with oc-
clusive artery disease, and 67 patients with deep venous thrombosis. 
Blood samples were collected and DNA was isolated from peripheral 
blood leukocytes. Identification of MTHFR mutations was done with 
CVD StripAssay (ViennaLab, Labordiagnostika GmbH, Vienna, Aus-
tria) and the population genetics analysis package, PyPop, was used for 
the analysis. Pearson P values, crude odds ratio, and Wald’s 95% confi-
dence intervals were calculated.
Results The frequency of C alleles of MTHFR-677 was 0.575 in pa-
tients with deep venous thrombosis, 0.612 in patients with occlusive 
artery disease, and 0.645 in healthy participants. The frequency of T al-
lele of MTHFR-677 was lower in healthy participants (0.355) than in 
patients with occlusive artery disease (0.388) and deep venous throm-
bosis (0.425). The frequency of A allele for MTHFR-1298 was 0.729 
in healthy participants, 0.770 in patients with occlusive artery disease, 
and 0.746 in patients with deep venous thrombosis. The frequency of 
C allele of MTHFR-1298 was 0.271 in healthy participants, 0.230 in 
patients with occlusive artery disease, and 0.425 in patients with deep 
venous thrombosis. No association of MTHFR-677 and MTHFR-
1289 polymorphisms with occlusive artery disease and deep venous 
thrombosis was found, except for the protective effect of MTHFR/CA:
CC diplotype for occlusive artery disease.
Conclusion We could not confirm a significant association of MTH-
FR-677 and MTHFR-1289 polymorphisms with occlusive artery dis-
ease or deep venous thrombosis in Macedonians, except for the pro-
tective effect of MTHFR/CA:CC diplotype against occlusive artery 
disease.
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Methylenetetrahydrofolate reductase (MTH-
FR; EC 1.5.1.20) catalyzes the conversion of 
5, 10-methylenetetrahydrofolate to 5-methyl-
tetrahydrofolate, a cosubstrate for homocyste-
ine remethylation to methionine. The human 
MTHFR gene (MIM *607093) has been local-
ized at chromosome 1p36.3 (1), and is com-
posed of 11 exons (2).
Twelve alleles of human MTHRF gene 
(0001-0012) have been identified so far 
(3). MTHFR thermolabile polymorphisms 
(MTHFR, 677C-T, ALA222VAL and MTH-
FR, 1298A-C, GLU429ALA) were investi-
gated in several diseases. The mutation in the 
heterozygous or homozygous state correlated 
with reduced enzyme activity and increased 
thermolability in lymphocyte extracts; in vi-
tro expression of the mutagenized cDNA con-
taining the mutation confirmed its effect on 
the thermolability of MTHFR. Individu-
als homozygous for the mutation had signifi-
cantly elevated plasma homocysteine levels. 
Thus, the 677C-T mutation may represent an 
important genetic risk factor for vascular dis-
ease (4-6). There are many articles connecting 
MTHFR mutations, mostly MTHFR 677C-
T, with plasma homocysteine levels. Several 
meta-analyses showed a positive association of 
MTHFR mutations with vascular diseases (7-
9), although several did not (10-12).
Since both mutations (677C-T and 
1298A-C MTHFR), when homozygous, were 
associated with a decreased DNA methylation 
status (although the effect was slightly less pro-
nounced for the 1298A-C transversion), it was 
suggested that 1298CC MTHFR genotype, in-
dependently of folate availability, and 677TT 
MTHFR genotype with concomitant low fo-
late levels, might be potential risk factors for 
diseases associated with decreased DNA meth-
ylation status (13).
We believe that MTHFR mutations influ-
ence the homocysteine metabolism, but are 
in weak association with vascular diseases and 
could be analyzed in combination with other 
candidate genes for vascular diseases. There are 
no data on MTHFR-677 and MTHFR-1298 
polymorphisms in Macedonian population 
and their possible associations with different 
diseases. The aim of this study was to analyze 
the association of methylenetetrahydrofolate 
reductase polymorphisms (MTHFR-677 and 
MTHFR-1298) with occlusive artery disease 
and deep venous thrombosis in order to inves-
tigate the role of MTHFR mutations as can-




The total studied sample consisted of 226 par-
ticipants, divided into three different groups 
as follows: healthy individuals, patients with 
occlusive artery disease, and patients with deep 
venous thrombosis.
Healthy individuals (n = 83). There were 
40 women and 43 men, aged 40.7 ± 11.3 years, 
born in different parts of Macedonia. They 
were age and sex non-matched healthy indi-
viduals who attended the Institute for Trans-
fusion for blood donation between May 5, 
2003 and April 25, 2004 and agreed to take 
part in this study as a control group if a med-
ical doctor declared their health as acceptable 
(on the basis of medical documentation, an in-
terview, and physical examination). Individu-
als with family history of blood vessel diseases 
were excluded from the investigation.
Occlusive artery disease (n = 76). There were 
29 women and 47 men with diagnosed and 
documented myocardial infarction (n = 52), 
brain infarction (n = 22), and peripheral artery 
thrombosis (n = 2). They were 63.3 ± 9.6 years 
old consecutive patients hospitalized at the In-
stitute of Heart Diseases, University School of 
Medicine, or attended the Institute for Trans-
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fusion for outpatient treatment between May 
5, 2003 and April 25, 2004.
Deep venous thrombosis (n = 67). There 
were 45 women and 22 men with a diagno-
sis of deep venous thrombosis made by ultra-
sonography and/or venography. They were 
57.7 ± 11.8 years old consecutive patients who 
attended the Institute of Heart Diseases, Uni-
versity School of Medicine and the Institute 
for Transfusion for outpatient treatment be-
tween May 5, 2003 and April 25, 2004.
All individuals were of Macedonian ori-
gin and residents of different geographical ar-
eas of the Republic of Macedonia. All patients 
and healthy individuals included in this study 
signed a written consent to participate in 
the study, which was approved by the Ethics 
Committee of the Ministry of Education and 
Science of the Republic of Macedonia (No. 
13-1672/4-02).
Genomic DNA isolation and storage
DNA was isolated from peripheral blood leu-
kocytes by phenol-chlorophorm extraction 
method or with BioRobot EZ1 workstation 
(QIAGEN) (14). The quality and quantity of 
DNA was analyzed by GeneQuant (Pharma-
cia Biotech, Uppsala, Sweden). Isolated DNA 
samples were stored in the Macedonian Hu-
man DNA Bank (15).
Typing methods
Assay for the identification of MTHFR mu-
tations was based on polymerase chain reac-
tion (PCR) and reverse-hybridization with 
CVD StripAssay (ViennaLab Labordiagnos-
tika GmbH, Vienna, Austria). The procedure 
included three steps as follows: 1) DNA isola-
tion; 2) PCR amplification using biotinylat-
ed primers; 3) hybridization of amplification 
products to a test strip containing allele-spe-
cific oligonucleotide probes immobilized as 
an array of parallel lines. Bound biotinylat-
ed sequences were detected using streptavi-
din-alkaline phosphatase and color substrates 
(16). The assay covered 2 mutations – MTH-
FR C677T and MTHFR A1298C. The geno-
type of the sample was determined using the 
enclosed Collector sheet or StripAssay Evalua-
tor software, version 2.0 (ViennaLab Diagnos-
tics GmbH).
Statistical analysis
The population genetics analysis package, Py-
Pop, developed by the Biostatistics Core for 
the Workshop (17-19), was used for analysis 
of the MTHFR data. Allele frequencies and ex-
pected Hardy Weinberg proportions (HWP) 
for each MTHFR mutation were determined 
(20). The exact test for genotype frequency de-
viation from HWP was performed, using the 
Arlequin implementation accessed via PyPop 
(21). The single nucleotide polymorphisms 
that deviated from HWP were evaluated to 
determine whether there was an excess of ho-
mozygotes or heterozygotes. χ2 test was used 
to determine if any particular genotypes were 
significantly different from the expected fre-
quencies. The Ewens-Watterson homozygos-
ity test of neutrality (22) with Slatkin’s exact 
P values (23,24) was used to indicate devia-
tions from the hypothesis of neutral selection 
for each locus. Linkage disequilibrium was cal-
culated, where D’ weights the contribution to 
linkage disequilibrium of specific allele pairs by 
the product of their allele frequencies; Wn is a 
re-expression of the χ2 statistic for deviations 
between the observed and expected haplotype 
frequencies; and S is defined as twice the dif-
ference between log-likelihood of obtaining 
the observed data given the inferred haplotype 
frequencies [ln(L_1)], and the likelihood of 
the data under the null hypothesis of linkage 
equilibrium [ln(L_0)]) (25). Pearson P values, 
crude odds ratio (OR), and Wald’s 95% confi-
dence interval (CI) were calculated to test the 
associations between MTHFR mutations and 
blood vessel disease with GraphPad Quick-
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Calcs – free statistical calculators (http://www.
graphpad.com/quickcalcs/). The level of statisti-
cal significance was set at P<0.05.
Results
MTHFR alleles
Frequencies of MTHFR alleles, test of neutral-
ity with Fnd statistic (Ewens-Watterson test of 
neutrality), and Slatkin’s Exact P Value with 
P of F statistics in Macedonians are shown in 
Table 1.
The frequency of C alleles for MTHFR-
677 varied between 0.575 for deep venous 
thrombosis, 0.612 for occlusive artery disease, 
and 0.645 for healthy participants, indicat-
ing a common wild type allele. The frequency 
of T allele was lower in healthy participants 
(0.355) than in patients with occlusive artery 
disease (0.388) or deep venous thrombosis 
(0.425). The frequency of A alleles for MTH-
FR-1298 varied from 0.729 for healthy par-
ticipants, 0.770 for patients with occlusive ar-
tery disease, and 0.746 for patients with deep 
venous thrombosis, indicating a common wild 
type allele. The frequency of C allele was 0.271 
in healthy participants, 0.230 in patients with 
occlusive artery disease, and 0.254 in patients 
with deep venous thrombosis. For all the 
MTHFR alleles, the test of neutrality showed 
negative value for Fnd statistics, without signif-
icant P of F statistics, which indicated balanc-
ing selection operating on the alleles at that lo-
cus in all the groups.
MTHFR genotypes
The most frequent MTHFR-677 genotype 
in healthy participants was CT, with the ob-
served frequency of 44.6%. A lower frequen-
cy was found for CC (42.2%) and the lowest 
(13.2%) for TT. The frequencies of MTH-
FR-677 CT and TT genotypes were slight-
ly increased in patients with occlusive artery 
disease and deep venous thrombosis, with a 
decrease in CC genotype (Table 2). All geno-
types in healthy participants and patients with 
blood vessel disease showed no deviation from 
HWP. The most frequent MTHFR-1298 gen-
otype in healthy participants was AA (49.4%). 
A lower frequency was found for CA geno-
type (47.0%) and the lowest for CC (3.6%). 
The frequency of MTHFR-1298 genotypes 
AA and CC was slightly increased in patients 
with occlusive artery disease and deep venous 
thrombosis, with a consecutive decrease in CA 
genotype. In some instances, χ2 test could not 
be performed because the expected frequency 
Table 1. Frequencies of MTHFR-677 and MTHFR-1298 alleles, test of neutrality with Fnd statistic (Ewens-Watterson test of neutrality), 
and Slatkin’s Exact P Value with P of F statistics in Macedonians*
Test of neutrality (F)
Alleles EWN SEPV
MTHFR mutation No. of patients allele number frequency Fnd P of F
MTHFR-677
Healthy 83 C 107 0.645 -1.696 0.106
T  59 0.355
Occlusive artery disease 76 C  93 0.612 -1.781 0.083
T  59 0.388
Deep venous thrombosis 67 C  77 0.575 -1.842 0.059
T  57 0.425
MTHFR-1298
Healthy 83 A 121 0.729 -1.320 0.176
C  45 0.271
Occlusive artery disease 76 A 117 0.770 -1.061 0.220
C  35 0.230
Deep venous thrombosis 67 A 100 0.746 -1.184 0.203
C  34 0.254
*Abbreviations: MTHFR – methylenetetrahydrofolate reductase; EWN – Ewens-Watterson test of neutrality; SEPV – Slatkin’s Exact P Value.
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was smaller than 5 (MTHFR-1298/CC in pa-
tients with occlusive artery disease and MTH-
FR-1298/CC in patients with deep venous 
thrombosis). All genotypes in healthy partic-
ipants and patients with blood vessel disease 
showed no deviations from HWP (Table 2).
MTHFR haplotypes and linkage disequilibrium
The most frequent haplotype of MTHFR-
677:MTHFR-1298 in healthy Macedonians 
was CA, followed by TA, CC, and TC (Table 
3). Similar haplotype frequencies were found 
patients with occlusive artery disease and deep 
venous thrombosis. Haplotypes of MTHFR-
677:MTHFR-1298 in healthy Macedonians, 
patients with occlusive artery disease, and in 
patients with deep venous thrombosis deviat-
ed from HWP (P<0.001 for all groups; Table 
3).
Observed vs expected MTHFR-677 and 
MTHFR-1298 diplotypes for each investigat-
ed group, χ2, and HWP in Macedonians are 
shown on Table 4. We observed 6 of possible 
10 diplotypes in all groups. Four expected dip-
lotypes (CC:TA, TC:TA, TC:CC, and TC:
TC) were not found in any of the groups. Be-
Table 2. Observed vs expected MTHFR-677 and MTHFR-1298 genotypes for each group, Hardy Weinberg proportions, and Guo and 
Thompson Hardy Weinberg Output in Macedonians*
Investigated group Genotype Observed number Observed frequency (%) Expected number P HWP P GTHWO P
MTHFR-677
Healthy 0.805 0.812
CC 35 42.2 34.5 0.930
CT 37 44.6 38.0 0.867
TT 11 13.2 10.5 0.874
Occlusive artery disease 0.483 0.630
CC 27 35.5 28.5 0.786
CT 39 51.3 36.1 0.629
TT 10 13.2 11.5 0.668
Deep venous thrombosis 0.575 0.803
CC 21 31.3 22.1 0.811
CT 35 52.2 32.8 0.695
TT 11 16.4 12.1 0.747
MTHFR-1298
Healthy 0.085 0.161
AA 41 49.4 44.1 0.641
CA 39 47.0 32.8 0.279
CC  3  3.6  6.1 0.209
Occlusive artery disease 0.688 0.522
AA 46 60.5 45.0 0.885
CA 25 32.9 26.9 0.708
CC  5  6.6  4.0 †
Deep venous thrombosis 0.320 0.203
AA 35 52.2 37.3 0.705
CA 30 44.8 25.4 0.358
CC  2  3.0  4.3 †
*Abbreviations: MTHFR – methylenetetrahydrofolate reductase; HWP – Hardy Weinberg proportions; GTHWO – Guo and Thompson Hardy Weinberg Output.
†Cannot be calculated because expected number was <5, χ2 test.
Table 3. Observed MTHFR-677 and MTHFR-1298 haplotypes 
for each group, χ2, and Hardy Weinberg proportions in Mace-
donians. The first nucleotide from haplotypes (C or T ) belongs 





























*MTHFR – methylenetetrahydrofolate reductase; HWP – Hardy Weinberg proportions.
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cause of that, most of the observed diplotypes 
in healthy Macedonians and in patients with 
deep venous thrombosis, except for MTH-
FR/CA:TA diplotype, deviated from HWP 
(P<0.05). In patients with occlusive artery 
disease, all diplotypes did not deviate from 
HWP, except for CA:TC and CC:TA diplo-
type (P<0.010; Table 4).
Linkage disequilibrium for the loci MTH-
FR-677:MTHFR-1298 was significant in 
healthy participants, participants with occlu-
sive artery disease, and participants with deep 
venous thrombosis (P<0.001; Table 5).
Association between MTHFR mutations and blood 
vessels diseases
We did not find a significant association be-
tween MTHFR-677 and MTHFR-1298 al-
leles or genotypes and occlusive artery disease 
(Pearson P>0.05; Table 6). There was also no 
Table 4. Observed vs expected MTHFR-677 and MTHFR-1298 diplotypes for each investigated group, χ2, and Hardy Weinberg propor-
tions in Macedonians. The first nucleotide from haplotypes (C or T ) belongs to MTHFR-677 and the second nucleotide (A or C) belongs 
to MTFHR-1298
Investigated group Diplotype Observed number Observed frequency (%) Expected Number χ2 HWP* P
Healthy
CA:CA  8  9.6 17.0  5.44  0.020
CA:TA 22 26.5 20.4  0.12  0.725
CA:CC 24 28.9 13.9  7.31  0.007
CA:TC 15 18.1  7.0  9.30  0.002
TA:TA 11 13.3  5.8  4.58  0.032
CC:TA  0  0  8.0  7.95  0.005
CC:CC  3  3.6  2.7  †  †
TC:TA  0  0  4.0  †  †
TC:CC  0  0  2.7  †  †
TC:TC  0  0  0.7  †  †
Occlusive artery disease
CA:CA 10 13.05 16.6  2.61  0.106
CA:TA 26 34.2 21.5  0.95  0.330
CA:CC 12 15.8 10.3  0.29  0.591
CA:TC 13 17.1  6.1  7.90  0.005
TA:TA 10 13.05  7.0  1.33  0.249
CC:TA  0  0  6.7  6.66  0.010
CC:CC  5  6.6  1.6  †  †
TC:TA  0  0  3.9  †  †
TC:CC  0  0  1.9  †  †
TC:TC  0  0  0.6  †  †
Deep venous thrombosis
CA:CA  6  8.9 13.4  4.11  0.043
CA:TA 18 26.9 17.9  0.00  0.983
CA:CC 13 19.4  7.6  3.81  0.051
CA:TC 17 25.4  7.6 11.58 <0.001
TA:TA 11 16.4  6.0  4.24  0.039
CC:TA  0  0  5.1  5.07  0.024
CC:CC  2  3.0  1.1  †  †
TC:TA  0  0  5.1  5.07  0.024
TC:CC  0  0  2.2  †  †
TC:TC  0  0  1.1  †  †
*MTHFR – methylenetetrahydrofolate reductase; HWP – Hardy Weinberg proportions.
†Cannot be calculated because expected number <5, χ2 test.
Table 5. Linkage disequilibrium for the loci MTHFR-677:MTHFR-1298*
Group D D’ Wn ln(L_1) ln(L_0) S P
Healthy 0.096 1.000 0.453 -138.55 -152.34 27.58 <0.001†
Occlusive artery disease 0.089 1.000 0.436 -127.76 -139.18 22.84 <0.001†
Deep venous thrombosis 0.108 1.000 0.502 -110.96 -122.23 22.54 <0.001†
*D’ weights the contribution to linkage disequilibrium of specific allele pairs by the product of their allele frequencies (25); Wn is a re-expression of the χ2 statistic for deviations between 
observed and expected haplotype frequencies; S is defined as twice the difference between log-likelihood of obtaining the observed data given the inferred haplotype frequencies 
[ln(L_1)], and the likelihood of the data under the null hypothesis of linkage equilibrium [ln(L_0)]); P value is the fraction of permutations that results in values of S greater or equal to 
that observed. P <0.05 is indicative of overall significant linkage disequilibrium.
†Significant values.
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significant association between MTHFR-667 
and MTHFR-1298 alleles or genotypes with 
deep venous thrombosis (Pearson P>0.05; 
Table 6).
We did not find a significant association 
between MTHFR haplotypes with occlusive 
artery disease (Pearson P>0.05; Table 7). We 
found a significant negative association be-
tween MTHFR/CA:CC diplotype and artery 
occlusive disease (P = 0.048; OR, 0.461; CI, 
0.212-1.003). The rest of MTHFR diplotypes 
were not significantly associated with occlusive 
artery disease. We did not find a significant as-
sociation between MTHFR haplotypes or dip-
lotypes with deep venous thrombosis (Pearson 
P>0.05; Table 7).
Discussion
Our study confirmed the presence of MTH-
FR-677, and MTHFR-1298 polymorphisms 
in Macedonian population, and their possible 
association with occlusive artery disease and 
deep venous thrombosis. There was no signif-
icant association of MTHFR-677 and MTH-
FR-1298 polymorphisms with occlusive artery 
disease or deep venous thrombosis, except the 
protective effect of MTHFR/CA:CC diplo-
type against occlusive artery disease.
We found negative Fnd for MTHFR-677 
and MTHFR-1298, but no significant P of F 
value, which indicates that balancing selection 
is operating on the alleles at that cluster. In all 
groups MTHFR-677 and MTHFR-1298 did 
not deviate from HWP, while MTHFR-677:
MTHFR-1298 haplotypes did. The same was 
true for MTHFR-677:MTHFR-1298 diplo-
types in all groups (with few exclusions). We 
observed 6 of 10 possible diplotypes in all the 
groups. Four expected diplotypes (CC:TA, 
TC:TA, TC:CC, and TC:TC) were not found 
in any of the groups. We found a significant 
linkage disequilibrium between the pair of 
MTHFR-677:MTHFR-1298 loci in healthy 
population, occlusive artery disease, and deep 
venous thrombosis. The absence of diplo-
Table 6. Association between MTHFR-677 and MTHFR-1298 alleles and genotypes with occlusive artery disease, Pearsons P value, 
crude odds ratio, and Wald’s 95% confidence interval (CI) in Macedonians*
 No. (%) of respondents
Allele or genotype with disease healthy (n = 83) Pearson P value Odds ratio Wald’s 95% CI
MTHFR-677: OAD (n = 76)
  C  93 (61.18) 107 (64.50) 0.563 1.151 0.730-1.812
  T  59 (38.82)  59 (35.50) 0.563 0.869 0.552-1.369
  CC  27 (35.52)  35 (42.20) 0.419 1.323 0.699-2.503
  CT  39 (51.32)  37 (44.60) 0.429 0.763 0.410-1.421
  TT  10 (13.16)  11 (13.20) 1.000 1.008 0.410-2.476
MTHFR-1298: OAD (n = 76)
  A 117 (77.0) 121 (72.9) 0.402 1.243 0.747-2.069
  C  35 (33.0)  45 (27.1) 0.402 0.804 0.483-1.339
  AA  46 (60.5)  41 (49.4) 0.159 1.571 0.837-2.949
  CA  25 (32.9)  39 (47.0) 0.070 0.553 0.290-1.053
  CC   5 (6.6)   3 (3.6) 0.393 1.878 0.433-8.140
MTHFR-677: DVT (n = 67)
  C  77 (57.46) 107 (64.50) 0.234 1.343 0.842-2.139
  T  57 (42.54)  59 (35.50) 0.234 0.745 0.467-1.187
  CC  21 (31.34)  35 (42.20) 0.180 1.597 0.816-3.124
  CT   35 (52.24)  37 (44.60) 0.412 0.735 0.387-1.399
  TT  11 (16.42)  11 (13.20) 0.646 0.778 0.320-1.888
MTHFR-1298: DVT (n = 67)
  A 100 (74.6) 121 (72.9) 0.734 1.094 0.651-1.836
  C  34 (25.4)  45 (27.1) 0.734 0.914 0.544-1.535
  AA  35 (52.2)  41 (49.4) 0.739 1.120 0.588-2.134
  CA  30 (44.8)  39 (47.0) 0.787 0.915 0.479-1.746
  CC   2 (3.0)   3 (3.6) 0.830 0.820 0.133-5.059
*Abbreviations: MTHFR – methylenetetrahydrofolate reductase; OAD – occlusive artery disease; DVT – deep venous thrombosis.
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types and significant linkage disequilibrium 
in Macedonians could be a result of selective 
pressures or low frequencies in the groups.
High frequency of MTHFR-677/TT gen-
otype (18-19%) was found in several studies 
conducted in Italy (4,26-28), while the low-
est frequency (6.2%) was found in Germany 
(29) and Croatia (6%) (30). The frequency of 
MTHFR-677/TT genotype in Greece was re-
ported in 16.7% of the population (31). Al-
lele and genotype frequencies of MTHFR-677 
in Macedonia were high compared with other 
European populations. Unfortunately, there 
are not enough data on the MTHFR-677 and 
MTHFR-1298 haplotypes and diplotypes to 
make reliable comparisons between popula-
tions, as well as association analysis with dif-
ferent diseases.
Geographic and ethnic distribution of the 
677C-T polymorphism in the MTHFR gene 
was studied in more than 7000 newborns 
from 16 areas in Europe, Asia, the Ameri-
cas, the Middle East, and Australia. The TT 
genotype was particularly common in north-
ern China (20%), southern Italy (26%), and 
Mexico (32%). There was also some evidence 
for geographic gradients in Europe (north to 
south increase) and China (north to south de-
crease). The TT genotype frequency was low 
among newborns of African origin, medi-
um among newborns of European origin, and 
high among newborns of American Hispanic 
origin. Areas with extreme frequencies showed 
deviations from HWP (Helsinki, southern It-
aly, and southern China). The findings sug-
gested the existence of selective pressures lead-
ing to a marked variation (32).
Several studies found a significant associa-
tion of MTHFR-677 and/or MTHFR-1298 
with blood vessel diseases, which is in discor-
dance with our data (7-9).
Non-significant association between 
MTHFR-677 and MTHFR-1298 alleles, gen-
otypes, haplotypes, and diplotypes with occlu-
sive artery disease and deep venous thrombosis 
found in our study is in agreement with most 
of the studies, especially on European popula-
tions (33-39). Caucasian patients are the most 
convenient for examining disease associations 
due to their greater genotype variability and 
larger number of patients with coronary ar-
tery disease. Our results suggest that neither 
677CT heterozygotes nor mutant homozy-
gotes have an increased or decreased risk for 
coronary artery disease, compared with 677CC 
genotype. Likewise, 1793GA genotype did not 
demonstrate a significant association with cor-
onary artery disease, compared with 1793GG 
patients (40).
A meta-analysis of the risk of coronary 
heart disease related to the 677C-T polymor-
phism showed that individuals with 677TT 
genotype have a significantly higher risk of 
coronary heart disease, particularly if they have 
a low folate status. These results supported the 
hypothesis that impaired folate metabolism, 
Table 7. Association between MTHFR-677:MTHFR-1298 hap-
lotypes and diplotypes with occlusive artery disease and deep 
venous thrombosis, Pearsons P-value, crude odds ratio (OR), 
and Wald’s 95% confidence interval (CI) in Macedonians*
No. of patients Wald’s
with disease healthy Pearson P OR 95% CI
Haplotypes: OAD (n = 152) (n = 166)
  CA 71 77 0.954 1.013 0.652-1.575
  CC 22 30 0.386 0.767 0.421-1.398
  TA 46 44 0.457 1.203 0.738-1.961
  TC 13 15 0.879 0.941 0.433-2.049
Diplotypes: OAD (n = 76) (n = 83)
  CA:CA 10 8 0.484 1.420 0.529-3.811
  CA:TA 26 22 0.290 1.442 0.731-2.845
  CA:CC 12 24 0.048 0.461 0.212-1.003
  CA:TC 13 15 0.873 0.935 0.413-2.120
  TA:TA 10 11 0.986 0.992 0.395-2.487
  CC:CC  5 3 0.393 1.878 0.433-8.14
Haplotypes: DVT (n = 134) (n = 166)
  CA 60 77 0.781 0.937 0.593-1.480
  CC 17 30 0.202 0.659 0.346-1.255
  TA 40 44 0.521 1.180 0.712-1.956
  TC 17 15 0.308 1.463 0.701-3.051
Diplotypes: DVT (n = 67) (n = 83)
  CA:CA  6 8 0.886 0.922 0.303-2.801
  CA:TA  18 22 0.960 1.019 0.492-2.108
  CA:CC 13 24 0.179 0.592 0.274-1.277
  CA:TC 17 15 0.278 1.541 0.703-3.377
  TA:TA 11 11 0.586 1.286 0.520-3.181
  CC:CC  2 3 0.831 0.820 0.133-5.059
*Abbreviations: MTHFR – methylenetetrahydrofolate reductase; OAD – occlusive 
artery disease; DVT – deep venous thrombosis.
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resulting in high homocysteine levels, is causal-
ly related to an increased risk of coronary heart 
disease (7-9). However, another meta-analy-
sis, which included case-control and prospec-
tive studies, found no association of MTHFR 
677 C→T polymorphism and coronary heart 
disease in Europe, North America, or Austra-
lia (10). In another study, eight candidate gene 
variants were analyzed in 32 431 individuals, 
comprising mainly Chinese, Japanese, and Ko-
rean individuals. Of eight candidate genes, the 
following three were associated with ischemic 
stroke: angiotensin I converting enzyme inser-
tion/deletion polymorphism in the Chinese 
and Japanese; C677T variant of 5,10- MTH-
FR in the Chinese and Koreans; and apolipo-
protein E gene in the Chinese and Japanese 
(11).
Cardiovascular system diseases are com-
plex genetic traits, which include hundreds of 
associated candidate genes (41). Our study of 
two mutations of a single gene (MTHFR-677 
and MTHFR-1298) can function as a begin-
ning of a complex investigation of candidate 
genes for cardiovascular diseases in Macedo-
nians. There is a possibility that positive results 
might be spurious and negative results a con-
sequence of low statistical power of our study. 
This could be due to the small sample size or 
methodological shortcomings, such as possible 
selection of an inappropriate control group. 
In order to have more precise conclusions for 
genetic background of cardiovascular diseases 
in Macedonians, it is necessary to investigate 
as many candidate genes as possible, in well-
defined subgroups of phenotypes, and with a 
larger number of participants.
In summary, the association of MTH-
FR-677, and MTHFR-1289 polymorphisms 
with occlusive artery disease and deep venous 
thrombosis in Macedonians was not found, 
except for the protective effect of MTHFR/
CA:CC diplotype on artery occlusive disease. 
The results can be used for population meta-
analysis, as well as for association studies with 
different diseases.
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